(GTBP) Takes Serious Measures to Help Ensure & Preserve Share Value Ahead of Potential NASDAQ Up-Listing
Today GT Biopharma (GTBP) filed an amendment to its previous warrant agreement and what was revealed could signal a major tipping point for the market. In today’s filing, the company formally indicated that its Warrant Holders cannot sell any warrants below $7 per share for a restricted period of time!
France Based Biotech Firm Raises $12M For Trials Of Aging Disease Treatments
France-based biotech company Biophytis completed its $12 million dollar raise it needs to begin mid-stage trials of two drugs for age-related diseases through a private placement. The company is headquartered in Paris and gained €10.4 million (nearly $12 million) from the private placement involving U.S, and European investors, and reported it will now move forward with its trial plans for sarcopenic obesity candidate Sarconeos (BIO101) and Macuneos (BIO201) for dry age-related macular degeneration (AMD).
GET ALERTS FASTER!
TEXT “BIOTECH” TO 474747 NOW!
BIOTECHSTOCKS,.com is owned by MIDAM VENTURES LLC., a Florida Corporation that has been compensated $800,000.00 by a GT Biopharma Inc. for a period beginning August 1, 2017 and ending Nov. 1, 2017 now extended to October 1, 2017 to publicly disseminate information about (GTBP). We own zero shares.